Bju Int

• 

  Publication Venue For

  • Development of an optically transparent kidney model for laser lithotripsy research. 2023
  • International Alliance of Urolithiasis guideline on retrograde intrarenal surgery..  131:153-164. 2023
  • Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer..  130:592-603. 2022
  • Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes..  128:196-205. 2021
  • Case of the Month from Duke University Medical Centre: a complete renal staghorn stone..  128:25-28. 2021
  • Estimating the health-related quality of life of kidney stone patients: initial results from the Wisconsin Stone Quality of Life Machine-Learning Algorithm (WISQOL-MLA)..  128:88-94. 2021
  • Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance..  123:846-853. 2019
  • Impact of bladder cancer on health-related quality of life..  121:549-557. 2018
  • Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer..  121:534-539. 2018
  • Female urethral injuries associated with pelvic fracture: a systematic review of the literature..  120:766-773. 2017
  • Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients..  119:896-904. 2017
  • Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer..  119:239-244. 2017
  • HOXB13 mutations and prostate cancer risk..  118:496-497. 2016
  • Hot topic of cancer survivorship and the 'seven deadly sins'..  116:310-311. 2015
  • Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC)..  116:17-29. 2015
  • A novel urodynamic model for lower urinary tract assessment in awake rats..  115 Suppl 6:8-15. 2015
  • Impact of comorbidity on health-related quality of life after prostate cancer treatment: combined analysis of two prospective cohort studies..  114:E74-E81. 2014
  • Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer..  114:E25-E31. 2014
  • Does body mass index impact the outcomes of tubeless percutaneous nephrolithotomy?.  114:404-411. 2014
  • Small renal mass biopsy--how, what and when: report from an international consensus panel..  113:854-863. 2014
  • Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy..  113:830-835. 2014
  • Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: Results from the SEARCH database.  n/a-n/a. 2014
  • The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel..  113:218-227. 2014
  • Treatment efficacy and outcomes using a third generation shockwave lithotripter..  112:972-981. 2013
  • Bilateral focal ablation of prostate tissue using low-energy direct current (LEDC): a preclinical canine study..  112:526-530. 2013
  • Emergent ureteric stent vs percutaneous nephrostomy for obstructive urolithiasis with sepsis: patterns of use and outcomes from a 15-year experience..  112:E122-E128. 2013
  • Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy..  110:E461-E468. 2012
  • C-reactive protein as a prognostic marker FOR mCRPC..  110:E469. 2012
  • Diagnostic tests in urology: an introduction..  110:E792-E793. 2012
  • Diagnostic tests in urology: urine cytology..  110:E789-E791. 2012
  • Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer..  110:1062-1069. 2012
  • Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel..  110:942-948. 2012
  • Uncertainty and perception of danger among patients undergoing treatment for prostate cancer. 2012
  • An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time..  110:375-381. 2012
  • Testosterone in prostate cancer: the Bethesda consensus..  110:344-352. 2012
  • Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer..  109:1636-1647. 2012
  • Complications and postoperative events after cryosurgery for prostate cancer..  109:840-845. 2012
  • Vitamin D(3) cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis..  109:949-958. 2012
  • Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group..  109 Suppl 1:22-29. 2012
  • Distal urethroplasty for isolated fossa navicularis and meatal strictures..  109:616-619. 2012
  • Dynamic prediction of metastases after radical prostatectomy for prostate cancer..  108:1762-1768. 2011
  • Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone..  108:1743-1749. 2011
  • Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry..  108:E196-E201. 2011
  • Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy..  108:1074-1085. 2011
  • Training in ureteroscopy: a critical appraisal of the literature..  108:798-805. 2011
  • Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men..  108:44-48. 2011
  • Clinical predictors of renal mass pathological features..  107:735-740. 2011
  • Randomized controlled, multicentre clinical trial comparing a dual-probe ultrasonic lithotrite with a single-probe lithotrite for percutaneous nephrolithotomy..  107:824-828. 2011
  • Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death..  106:1618-1622. 2010
  • Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer..  106:1623-1627. 2010
  • How does sipuleucel-T alter our clinical practice?.  106:945-946. 2010
  • Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans..  106:1157-1160. 2010
  • External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: results from the Duke Prostate Center Database..  106:796-800. 2010
  • Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology..  106:462-469. 2010
  • Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study..  106:182-187. 2010
  • Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy..  105:1654-1659. 2010
  • Regional variations in small intestinal submucosa evoke differences in inflammation with subsequent impact on tissue regeneration in the rat bladder augmentation model..  105:1462-1468. 2010
  • Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended..  105:1089-1092. 2010
  • Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy..  105:191-201. 2010
  • Robot-assisted laparoscopic prostatectomy is not associated with early postoperative radiation therapy..  104:1496-1500. 2009
  • Erectile function after posterior urethroplasty for pelvic fracture-urethral distraction defect injuries..  104:1126-1129. 2009
  • Evidence-based urology in practice: likelihood ratios..  104:892-894. 2009
  • High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure..  104:1058-1062. 2009
  • Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up..  104:310-314. 2009
  • Evidence-based medicine training in residency: a survey of urology programme directors..  103:290-293. 2009
  • Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases..  102:969-974. 2008
  • Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer..  102:546-550. 2008
  • Ejaculatory profiles and fertility in men after posterior urethroplasty for pelvic fracture-urethral distraction defect injuries..  102:351-353. 2008
  • How long is too long? The effect of the duration of anaesthesia on the incidence of non-urological complications after surgery..  102:301-304. 2008
  • Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy..  102:28-32. 2008
  • Differences in urinary incontinence between Hispanic and non-Hispanic white women: a population-based study..  101:575-579. 2008
  • A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102..  101:20-25. 2008
  • After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer..  101:170-174. 2008
  • Micro-percutaneous nephrolithotomy (micro-PNL) vs retrograde intra-renal surgery (RIRS): dealer's choice? The devil is in the details..  112:280-281. 2013
  • Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy..  111:187-188. 2013
  • Comprehensive preoperative evaluation and repair of inguinal hernias at the time of open radical retropubic prostatectomy decreases risk of developing postprostatectomy hernia..  110:E607. 2012
  • Maximizing outcomes in genitourinary cancers across the treatment continuum..  107 Suppl 2:1-12. 2011
  • Twenty-five year evolution of medical hormonal therapy for prostate cancer..  103:145-146. 2009